Covid-19: Moderna launches clinical trials on children
The American laboratory Moderna has announced the launch of a clinical trial to evaluate the effectiveness of its vaccine against Covid-19 on children.
Vaccination of children against Covid-19
The phase 2/3 study will start soon. To do this, Moderna plans to recruit 6,750 “pediatric participants” to test its anti-Covid messenger RNA vaccine on minors. The young participants, aged 6 months to 12 years, of American and Canadian origin, will therefore make their contribution to the project, called KidCOVE. Two injections will be administered, spaced four weeks apart. Children aged 2 to under 12 will receive one of two dose levels of the vaccine (50 mcg or 100 mcg). Participants six months to less than two years of age may receive one of three dose levels (25 mcg, 50 mcg, and 100 mcg). A dose adjustment will be made if necessary. The children will be followed for 12 months after the second injection. In the laboratory press release, Stéphane Bancel, CEO of Moderna said that 'We are pleased to begin this phase 2/3 study of mRNA-1273 in healthy children. This clinical trial will 'assess the potential safety and immunogenicity of our vaccine candidate in this large, younger age population.'
Since December, the Moderna laboratory has been carrying out clinical trials of its vaccine against Covid-19 on adolescents, aged between 12 and 18 years.
No comments:
Post a Comment